Ehsan Irajizad

1.0k total citations
31 papers, 318 citations indexed

About

Ehsan Irajizad is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ehsan Irajizad has authored 31 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Ehsan Irajizad's work include Lung Cancer Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Ehsan Irajizad is often cited by papers focused on Lung Cancer Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Ehsan Irajizad collaborates with scholars based in United States, Japan and Canada. Ehsan Irajizad's co-authors include Johannes F. Fahrmann, Samir Hanash, Jody V. Vykoukal, Jennifer B. Dennison, Eunice Murage, Edwin J. Ostrin, Hiroyuki Katayama, James P. Long, Nikul Patel and Ashutosh Agrawal and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Ehsan Irajizad

24 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ehsan Irajizad United States 10 193 92 80 77 45 31 318
Mykola Chekan Poland 15 290 1.5× 113 1.2× 36 0.5× 67 0.9× 17 0.4× 20 484
Shuangtao Zhao China 12 239 1.2× 157 1.7× 76 0.9× 94 1.2× 31 0.7× 35 436
Kelly M. Redmond United Kingdom 9 273 1.4× 69 0.8× 120 1.5× 136 1.8× 61 1.4× 17 447
Tomasz Tyszkiewicz Poland 11 180 0.9× 99 1.1× 52 0.7× 70 0.9× 10 0.2× 20 319
Chenyi Zhou China 11 196 1.0× 71 0.8× 62 0.8× 95 1.2× 12 0.3× 20 299
Yi Su China 12 374 1.9× 100 1.1× 72 0.9× 72 0.9× 21 0.5× 20 514
Tsunehisa Nomura Japan 9 121 0.6× 80 0.9× 37 0.5× 137 1.8× 25 0.6× 33 292
Nadia Vié France 7 201 1.0× 105 1.1× 54 0.7× 164 2.1× 42 0.9× 10 362
Sofie H Willems Netherlands 5 144 0.7× 75 0.8× 37 0.5× 124 1.6× 53 1.2× 8 330
Nakako Izumi Nakajima Japan 9 189 1.0× 66 0.7× 139 1.7× 91 1.2× 75 1.7× 14 297

Countries citing papers authored by Ehsan Irajizad

Since Specialization
Citations

This map shows the geographic impact of Ehsan Irajizad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ehsan Irajizad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ehsan Irajizad more than expected).

Fields of papers citing papers by Ehsan Irajizad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ehsan Irajizad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ehsan Irajizad. The network helps show where Ehsan Irajizad may publish in the future.

Co-authorship network of co-authors of Ehsan Irajizad

This figure shows the co-authorship network connecting the top 25 collaborators of Ehsan Irajizad. A scholar is included among the top collaborators of Ehsan Irajizad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ehsan Irajizad. Ehsan Irajizad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fahrmann, Johannes F., Michele Yip-Schneider, Jennifer B. Dennison, et al.. (2025). Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Cancer Letters. 612. 217450–217450. 4 indexed citations
2.
Mosley, Amber L., Ehsan Irajizad, Michele Yip-Schneider, et al.. (2025). Cyst fluid proteins stratify malignant risk of intraductal papillary mucinous neoplasm of the pancreas. Cancer Letters. 624. 217753–217753.
3.
Chen, Yihui, Rongzhang Dou, Ehsan Irajizad, et al.. (2025). Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression. Clinical Cancer Research. 31(12). 2454–2465.
4.
Irajizad, Ehsan, James P. Long, Johannes F. Fahrmann, et al.. (2025). Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials. Journal of Thoracic Oncology. 20(5). 565–576. 3 indexed citations
5.
Fahrmann, Johannes F., et al.. (2025). SMAGS-LASSO: A Novel Feature Selection Method for Sensitivity Maximization in Early Cancer Detection. Cancer Epidemiology Biomarkers & Prevention. 34(12). 2259–2266.
6.
Bataller, Álex, Bofei Wang, Courtney D. DiNardo, et al.. (2025). Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. Leukemia & lymphoma. 66(7). 1221–1233.
7.
8.
Niu, Jiangong, Martin C. Tammemägi, Ehsan Irajizad, et al.. (2024). Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. JNCI Journal of the National Cancer Institute. 116(11). 1798–1806. 4 indexed citations
9.
Irajizad, Ehsan, Iakovos Toumazis, Jody V. Vykoukal, et al.. (2024). Biomarker trajectory for earlier detection of lung cancer. EBioMedicine. 108. 105377–105377. 2 indexed citations
10.
Song, Lulu, Ehsan Irajizad, Andrew Rundle, et al.. (2024). Validation of a Blood-Based Protein Biomarker Panel for a Risk Assessment of Lethal Lung Cancer in the Physicians’ Health Study. Cancers. 16(11). 2070–2070. 1 indexed citations
11.
Chen, Yihui, Ranran Wu, Ehsan Irajizad, et al.. (2023). Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis. Cancers. 15(3). 834–834. 18 indexed citations
12.
Irajizad, Ehsan, Johannes F. Fahrmann, Tracey L. Marsh, et al.. (2023). Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort. Journal of Clinical Oncology. 41(27). 4360–4368. 10 indexed citations
13.
Fahrmann, Johannes F., Ehsan Irajizad, Edwin J. Ostrin, et al.. (2023). Mortality benefit of a blood-based biomarker panel for lung cancer and the PLCO cohort.. Journal of Clinical Oncology. 41(16_suppl). 8560–8560. 1 indexed citations
14.
Long, James P., et al.. (2023). A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes. Bioinformatics. 39(1). 2 indexed citations
15.
Fahrmann, Johannes F., Tracey L. Marsh, Ehsan Irajizad, et al.. (2022). Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. Journal of Clinical Oncology. 40(8). 876–883. 57 indexed citations
16.
Irajizad, Ehsan, Chae Young Han, Joseph Celestino, et al.. (2022). A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses. Clinical Cancer Research. 28(21). 4669–4676. 10 indexed citations
17.
Fahrmann, Johannes F., Hiroyuki Katayama, Ehsan Irajizad, et al.. (2021). Plasma Based Protein Signatures Associated with Small Cell Lung Cancer. Cancers. 13(16). 3972–3972. 6 indexed citations
18.
Fahrmann, Johannes F., Xiangying Mao, Ehsan Irajizad, et al.. (2020). Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. Cancers. 12(5). 1147–1147. 20 indexed citations
19.
Vykoukal, Jody V., Johannes F. Fahrmann, Justin R. Gregg, et al.. (2020). Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nature Communications. 11(1). 4279–4279. 50 indexed citations
20.
Kobayashi, Makoto, Hiroyuki Katayama, Ehsan Irajizad, et al.. (2020). Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers. 12(2). 485–485. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mykola Chekan Breakdown of academic impact, for papers by Shuangtao Zhao Breakdown of academic impact, for papers by Kelly M. Redmond Breakdown of academic impact, for papers by Tomasz Tyszkiewicz Breakdown of academic impact, for papers by Chenyi Zhou Breakdown of academic impact, for papers by Yi Su Breakdown of academic impact, for papers by Tsunehisa Nomura Breakdown of academic impact, for papers by Nadia Vié Breakdown of academic impact, for papers by Sofie H Willems Breakdown of academic impact, for papers by Nakako Izumi Nakajima
Rankless by CCL
2026